
Qualification of a Semi-Automated Cell-Based Potency Assay for mRNA (Case Study)
Posters
Information
Presented by:
Roger Müller, Eurofins Biopharma Product Testing
Poster Number: P-105-W
Poster Session:
Antibody Products and Automation
Wednesday, 24 Sept. at 15:00
-----
Cell-based potency assays rely on living cells, involve multiple pipetting steps, and require the handling of small volumes - all factors that contribute to the inherent variability within assays, between analysts, and across different days. To mitigate these challenges, we implemented semi-automation using instruments such as the Integra VIAFLO96 and Integra ASSIST PLUS.
In our case study, we developed a potency expression assay in which mRNA is transfected into a suitable host cell line, and intracellular protein expression is quantified via ELISA. Following method optimization and the integration of semi-automation - necessitated by the complexity and the number of procedural steps - the method was subsequently qualified in accordance with the ICH Q2(R2) guideline, demonstrating acceptable accuracy, precision, linearity, and specificity.
Semi-automation significantly enhances potency assay performance by increasing throughput and reducing analyst hands-on time, while maintaining accuracy and precision comparable to manual methods. This case study highlights the potential of modular automation to improve bioassay efficiency, reduce manual workload, and support reliable quality control in biopharmaceutical manufacturing.
